Sanquin Plasma Revenue and Competitors
Estimated Revenue & Valuation
- Sanquin Plasma's estimated annual revenue is currently $24.3M per year.
- Sanquin Plasma's estimated revenue per employee is $201,000
Employee Data
- Sanquin Plasma has 121 Employees.
- Sanquin Plasma grew their employee count by -31% last year.
Sanquin Plasma's People
| Name | Title | Email/Phone |
|---|
Sanquin Plasma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $14.7M | 73 | 6% | N/A | N/A |
#2 | $49.4M | 246 | 13% | N/A | N/A |
#3 | $51.3M | 255 | -1% | N/A | N/A |
#4 | $34.6M | 172 | 8% | N/A | N/A |
#5 | $251.3M | 1250 | 6% | N/A | N/A |
#6 | $4.6M | 23 | 44% | N/A | N/A |
#7 | $251.3M | 1250 | 6% | N/A | N/A |
#8 | $24.3M | 121 | -31% | N/A | N/A |
#9 | $90.7M | 451 | -8% | N/A | N/A |
#10 | $2.4M | 12 | 20% | N/A | N/A |
What Is Sanquin Plasma?
From our home base in Amsterdam, the Netherlands, Sanquin Plasma Products B.V. produces and exports a broad range of pharmaceuticals for patients throughout the world. Our pharmaceuticals are derived from blood plasma and used for a large number of disorders, many of which life-threatening.
keywords:N/A
N/A
Total Funding
121
Number of Employees
$24.3M
Revenue (est)
-31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sanquin Plasma News
CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), LFB (France), Biotest (Germany), Sanquin...
Some of the Top companies Influencing in this Market include:CSL, ADMA Biologics, Sanquin, Baxter International, Octapharma, Cerus Corp,...
Plasma Protease C1-inhibitor Treatment Market Size, Share, Growth 2022-2029| Key Players Shire plc, CSL Limited, Sanquin, Pharming Group N.V..
Other Companies in Amsterdam
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $25.4M | 121 | -10% | N/A |
#2 | $16.9M | 121 | -9% | N/A |
#3 | $17.1M | 122 | 42% | N/A |
#4 | $25.6M | 122 | 27% | N/A |
#5 | $30.5M | 122 | 1% | N/A |